| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: there are described new triazolium salts of general formula (I) stereo- and tautomer forms and physiologically acceptable salts thereof, wherein X- C-R1 or N, R1-hydrogen, C 1-6 alkyl or halogen; A - is an anion of a pharmacologically acceptable organic or inorganic acid; Q1 is hydrogn, -C 1-6 alkyl optionally substituted, -C 3-6 cycloalkyl, -C(O)-O-R11 or - C(O)-R11; R11 -C 1-6 alkyl; Q2 and Q3 are hydrogen; R2- R9 independently mean hydrogen, -C 1-6 alkyl optionally substituted, -O-(C 1-8 )alkyl optionally substituted, etc., and using the above compounds as a drug preparation. n EFFECT: compounds possess antithrombotic activity, particularly, they inhibit the protease-activated receptor 1 (PAR1), and may be used in treating the diseases such as myocardial infarction, angina, stroke, and others. n 4 cl, 2 tbl, 86 ex |